Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
431. |
ECCT/23/10/01 | CROSSWALK Chronic (C) A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c) |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Doreen Terry Karimi Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
432. |
ECCT/19/03/05 | EPI-MAL-003 (Siaya) A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya |
Principal Investigator(s) 1. Simon Kariuki 2. Martina Oneko Site(s) in Kenya 1. Bondo sub-county (Siaya county) 2. Gem sub-county (Siaya county) |
View |
433. |
ECCT/22/03/07 | ELEVATUM A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA |
Principal Investigator(s) 1. Dr. Oscar Muwale Onyango 2. Dr. Muchai Gachago Site(s) in Kenya 1. The Nairobi Hospital (Nairobi City county) 2. City Eye Hospital (Nairobi City county) |
View |
434. |
ECCT/23/01/01 | PROHER A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2-POSITIVE BREAST CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
435. |
ECCT/22/12/03 | heredERA A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |